Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seralutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R known ✓ | P07333 | 16/20 | 0.72 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.59 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.59 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FRK | P42685 | 1/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | LDHB | P07195 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seralutinib SCHEMBL29415597 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL20100984 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL30738060 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL17324860 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL18023958 | 0.96 | CSF1R (0.69) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL19447311 | 0.94 | CSF1R (0.67) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL17324861 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20100981 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20100983 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL13339930 | 0.94 | CSF1R (0.66) | CSF1RRETPDGFRBKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117157282-A | Crystalline forms of N- {3- [ (1S) -1- { [6- (3, 4-dimethoxyphenyl) pyrazin-2-yl ] amino } ethyl ] phenyl } -5-methylpyridine-3-carboxamide and related products and methods | GB002股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20240228462-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2- YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB002 INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228462-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2- YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB002 INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4334300-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2-YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB005, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334300-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2-YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB005, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117157282-A | Crystalline forms of N- {3- [ (1S) -1- { [6- (3, 4-dimethoxyphenyl) pyrazin-2-yl ] amino } ethyl ] phenyl } -5-methylpyridine-3-carboxamide and related products and methods | GB002股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117157282-A | Crystalline forms of N- {3- [ (1S) -1- { [6- (3, 4-dimethoxyphenyl) pyrazin-2-yl ] amino } ethyl ] phenyl } -5-methylpyridine-3-carboxamide and related products and methods | GB002股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117157282-A | Crystalline forms of N- {3- [ (1S) -1- { [6- (3, 4-dimethoxyphenyl) pyrazin-2-yl ] amino } ethyl ] phenyl } -5-methylpyridine-3-carboxamide and related products and methods | GB002股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3054937-B1 | SPRAY DRY FORMULATIONS | PULMOKINE INC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022236139-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2-YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB002, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11364238-B2 | Combination therapy for treating pulmonary hypertension | PULMOKINE, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019157337-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | PULMOKINE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018081567-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. | 2018-05-03 | — | — | US | disclosed |
| EP-3007689-B1 | NON-SELECTIVE KINASE INHIBITORS | PULMOKINE INC (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017083425-A1 | METHODS OF DETECTING AND TREATING PULMONARY HYPERTENSION | Rensselaer Center for Translational Research, Inc. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228462-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2- YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | PHKG1, PHKG2, MAP4K5 | CSF1R 3383/4885PDGFRB 767/4885KIT 328/4885 |
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885KIT 159/4885 |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PTGIR, PTGIS, PTGFR | CSF1R 1178/4885PDGFRB 5/4885KIT 279/4885 |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885KIT 159/4885 |
| US-11364238-B2 | Combination therapy for treating pulmonary hypertension | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885KIT 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.